Within ninety minutes of a single intranasal dose, Semax can increase BDNF mRNA expression in the rat hippocampus several-fold — a magnitude of neurotrophic induction normally associated with sustained exercise or antidepressant therapy lasting weeks. This speed of action, combined with its origin as a fragment of adrenocorticotropic hormone stripped of its endocrine activity, makes Semax one of the most studied nootropic peptides in Russian neuropharmacology and a compound of growing interest in Western cognitive enhancement research.
What Is Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, corresponding to a modified fragment of adrenocorticotropic hormone (ACTH), specifically ACTH(4-7), extended with a C-terminal Pro-Gly-Pro tripeptide. The Pro-Gly-Pro tail dramatically extends the peptide’s half-life in plasma and central nervous tissue by resisting enzymatic degradation, while the ACTH(4-7) core retains the neurotropic activity of the parent hormone without its corticosteroid-releasing endocrine effects.[1]
Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and is registered in Russia for treatment of transient ischemic attacks, ischemic stroke, cognitive disorders, and optic nerve atrophy. It is most commonly administered as a 0.1% or 1% intranasal solution, which bypasses first-pass hepatic metabolism and allows rapid penetration into the central nervous system via the olfactory and trigeminal nerve pathways.[2]
How Semax Works
BDNF and NGF Upregulation: The most distinctive mechanism of Semax is its ability to rapidly induce expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and basal forebrain. Studies in rats demonstrate that a single intranasal dose produces significant increases in BDNF mRNA and protein within 3 hours, with effects persisting for 24 hours or longer. This neurotrophic induction is thought to underlie the peptide’s effects on synaptic plasticity, memory consolidation, and neuronal survival under ischemic stress.[3]
Dopaminergic Modulation: Semax modulates dopaminergic transmission in the prefrontal cortex and striatum. Microdialysis studies show that Semax administration increases extracellular dopamine and its metabolites (DOPAC and HVA) in cortical regions, an effect mediated in part by altered tyrosine hydroxylase activity and possibly by inhibition of enkephalin-degrading enzymes that indirectly regulate dopamine release.[4]
Enkephalinase Inhibition: Semax inhibits the enzymatic degradation of endogenous regulatory peptides, particularly enkephalins, by inhibiting prolyl endopeptidase and related peptidases. This prolongs the activity of enkephalins and other neuromodulatory peptides, contributing to its effects on mood, attention, and stress resilience.[1]
Serotonergic Effects: Semax increases serotonin turnover in the frontal cortex and hippocampus, an effect that may contribute to its anxiolytic and antidepressant-like properties observed in preclinical models. Unlike SSRIs, the serotonergic effect is indirect and occurs alongside dopaminergic activation — a combination that may explain the cognitive activating rather than sedating profile.[4]
ACTH Receptor Independence: Although derived from ACTH, Semax does not significantly activate melanocortin receptors at therapeutic doses, which explains the absence of cortisol elevation. This dissociation of neurotropic from endocrine activity was a deliberate design goal of the parent ACTH(4-10) fragment research program.[2]
Clinical and Research Evidence
Ischemic Stroke: The largest body of clinical evidence for Semax comes from Russian trials in acute ischemic stroke. A multicenter study demonstrated that intranasal Semax administered within the first hours of stroke onset improved neurological recovery scores and reduced the volume of infarcted tissue compared with standard care. The proposed mechanism involves both direct neuroprotection via BDNF induction and modulation of inflammatory gene expression in penumbral tissue.[5]
Cognitive Performance in Healthy Subjects: Studies in healthy human volunteers have shown that Semax improves performance on attention-demanding tasks, particularly under conditions of fatigue or operator stress. Effects have been documented on selective attention, working memory, and reaction time, with improvements typically appearing 30–60 minutes after intranasal administration and persisting for several hours.[2]
Gene Expression Profiling: Transcriptomic analyses in rat brain tissue have shown that Semax acutely alters expression of hundreds of genes involved in neurotrophic signaling, vascular remodeling, and immune modulation. Notably, Semax upregulates genes encoding neurotrophins and their receptors (TrkB, p75) while downregulating pro-apoptotic and pro-inflammatory transcripts — a pattern consistent with a neuroprotective phenotype.[3]
Optic Neuropathy: Semax has been studied in optic nerve atrophy and ischemic optic neuropathy, where its NGF-inducing activity is thought to support retinal ganglion cell survival. Open-label studies report improvements in visual acuity and visual evoked potential amplitudes, though large randomized trials in Western populations are lacking.[2]
Safety Profile
Semax has an unusually benign safety record in the published literature. Decades of clinical use in Russia, including in pediatric populations for attention disorders, have not surfaced significant adverse signals. The most commonly reported side effects are mild and local — nasal irritation, transient headache, and occasional mild stimulation or sleep disturbance if dosed late in the day.
Because Semax does not meaningfully activate melanocortin receptors, it does not produce cortisol elevation, blood pressure changes, or skin pigmentation effects seen with other ACTH-derived compounds. There are no published reports of dependence or withdrawal, and tolerance to its cognitive effects does not appear to develop rapidly, though most controlled studies are of short duration.
Caution is warranted in patients with active psychiatric conditions, particularly those involving dopaminergic dysregulation such as psychotic disorders, given the peptide’s effect on cortical dopamine. Semax has not been adequately studied in pregnancy, and intranasal administration in patients with active rhinosinusitis or nasal mucosal disease may result in unpredictable absorption.
Semax vs Other Cognitive Peptides and Nootropics
vs Selank: Selank is a related Russian-developed heptapeptide derived from tuftsin rather than ACTH. While Selank is primarily anxiolytic and modulates GABAergic and enkephalinergic systems, Semax is more activating and produces greater dopaminergic and neurotrophic effects. The two are sometimes used in complementary fashion, with Selank addressing anxiety and Semax targeting attention and cognitive performance.
vs Cerebrolysin: Cerebrolysin is a porcine brain-derived peptide mixture used for stroke and dementia. While Cerebrolysin also exerts neurotrophic effects, its composition is heterogeneous and its mechanism less defined. Semax offers a single, well-characterized molecular entity with a more specific BDNF/NGF induction profile and the practical advantage of intranasal rather than parenteral administration.
vs Racetams: Piracetam and related racetams have been used as nootropics for decades but produce modest effects via poorly understood mechanisms involving membrane fluidity and cholinergic modulation. Semax acts through a distinct neurotrophic pathway and produces measurable gene expression changes that racetams do not, though direct head-to-head comparisons are limited.
vs Exercise-Induced BDNF: Aerobic exercise remains the most robust physiological inducer of BDNF, with effects on cognition and mood that integrate metabolic, vascular, and neurotrophic mechanisms. Semax does not replicate the systemic benefits of exercise but offers a pharmacological route to acute BDNF induction that may be useful in patients unable to exercise or during acute neurological insults.
References
- Ashmarin IP, et al. “Nootropic analogues of adrenocorticotropin 4-10 (semax) (15-year experience in design and study).” Zhurnal Vysshei Nervnoi Deyatelnosti. 1997;47(2):420-430.
- Kaplan AY, et al. “Synthetic ACTH analogue Semax displays nootropic-like activity in humans.” Neuroscience Research Communications. 1996;19(2):115-123.
- Shadrina MI, et al. “Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog.” Neuroscience Letters. 2001;308(2):115-118.
- Eremin KO, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005;30(12):1493-1500.
- Gusev EI, et al. “Neuroprotective effects of semax in acute ischemic stroke.” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2005;105(3):24-28.
